

Alejandro Gonzalez-Serna

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2509454/publications.pdf>

Version: 2024-02-01

24
papers

429
citations

840728

11
h-index

713444

21
g-index

24
all docs

24
docs citations

24
times ranked

715
citing authors

#	ARTICLE	IF	CITATIONS
1	Performance of HIV-1 Drug Resistance Testing at Low-Level Viremia and Its Ability to Predict Future Virologic Outcomes and Viral Evolution in Treatment-Naive Individuals. <i>Clinical Infectious Diseases</i> , 2014, 58, 1165-1173.	5.8	77
2	HIV drug resistance detected during low-level viraemia is associated with subsequent virologic failure. <i>Aids</i> , 2014, 28, 1125-1134.	2.2	72
3	Different biological significance of sCD14 and LPS in HIV-infection: Importance of the immunovirology stage and association with HIV-disease progression markers. <i>Journal of Infection</i> , 2012, 65, 431-438.	3.3	41
4	Correlation between the Trofile(R) test and virological response to a short-term maraviroc exposure in HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 845-849.	3.0	28
5	Temporal trends in the discontinuation of first-line antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2202-2209.	3.0	24
6	TROCAI (Tropism Coreceptor Assay Information): a New Phenotypic Tropism Test and Its Correlation with Trofile Enhanced Sensitivity and Genotypic Approaches. <i>Journal of Clinical Microbiology</i> , 2010, 48, 4453-4458.	3.9	21
7	A single untimed plasma drug concentration measurement during low-level HIV viremia predicts virologic failure. <i>Clinical Microbiology and Infection</i> , 2016, 22, 1004.e9-1004.e16.	6.0	21
8	Rapid Decrease in Peripheral Blood Mononucleated Cell Telomere Length After HIV Seroconversion, but Not HCV Seroconversion. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, e29-e32.	2.1	20
9	Correlation of the Virological Response to Short-Term Maraviroc Monotherapy with Standard and Deep-Sequencing-Based Genotypic Tropism Prediction Methods. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 1202-1207.	3.2	19
10	Effect of Maraviroc on HIV Disease Progression-Related Biomarkers. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5858-5864.	3.2	19
11	Long-Term Immunovirological Effect and Tolerability of a Maraviroc-Containing Regimen in Routine Clinical Practice. <i>Current HIV Research</i> , 2010, 8, 482-486.	0.5	17
12	Virological Response after Short-Term CCR5 Antagonist Exposure in HIV-Infected Patients: Frequency of Subjects with Virological Response and Associated Factors. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 4664-4669.	3.2	11
13	Discordance rates between Trofile® test and short-term virological response to maraviroc. <i>Antiviral Research</i> , 2011, 89, 182-185.	4.1	10
14	CD8 TCR β chain repertoire expansions and deletions are related with immunologic markers in HIV-1-infected patients during treatment interruption. <i>Journal of Clinical Virology</i> , 2013, 58, 703-709.	3.1	9
15	HIV-1 Tropism Evolution after Short-Term Maraviroc Monotherapy in HIV-1-Infected Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 3981-3983.	3.2	7
16	Patients on a combined antiretroviral therapy after maraviroc clinical test show no immunovirological impairment. <i>Antiviral Research</i> , 2012, 95, 207-211.	4.1	6
17	Increased CD127+ and decreased CD57+ T cell expression levels in HIV-infected patients on NRTI-sparing regimens. <i>Journal of Translational Medicine</i> , 2017, 15, 259.	4.4	6
18	Genotypic susceptibility score (GSS) and CD4+ T cell recovery in HIV-1 patients with suppressed viral load. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 496-503.	3.0	5

#	ARTICLE	IF	CITATIONS
19	Relationship between CCR5(WT/Δ32) heterozygosity and HIV-1 reservoir size in adolescents and young adults with perinatally acquired HIV-1 infection. <i>Clinical Microbiology and Infection</i> , 2017, 23, 318-324.	6.0	5
20	A genome-wide association study on low susceptibility to hepatitis C virus infection (GEHEP012 study). <i>Liver International</i> , 2019, 39, 1918-1926.	3.9	4
21	“Test-and-Treat” Strategy for Control of HIV and AIDS Can Lead to a Decrease, Not an Increase, of Multidrug-Resistant Viruses. <i>Clinical Infectious Diseases</i> , 2013, 57, 478-479.	5.8	3
22	Short-term maraviroc exposure, a clinical approach to decide on maraviroc prescription in HIV-1-infected treatment-naïve patients. <i>Drug Design, Development and Therapy</i> , 2016, 10, 353.	4.3	2
23	A Genome-Wide Association Study on Liver Stiffness Changes during Hepatitis C Virus Infection Cure. <i>Diagnostics</i> , 2021, 11, 1501.	2.6	2
24	Validation of the HIV Tropism Test TROCAI Using the Virological Response to a Short-Term Maraviroc Monotherapy Exposure. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6398-6401.	3.2	0